Variation of breast cancer risk among BRCA1/2 carriers
- PMID: 18182601
- PMCID: PMC2714486
- DOI: 10.1001/jama.2007.55-a
Variation of breast cancer risk among BRCA1/2 carriers
Abstract
Context: The risk of breast cancer in BRCA1 and BRCA2 mutation carriers has been examined in many studies, but relatively little attention has been paid to the degree to which the risk may vary among carriers.
Objectives: To determine the extent to which risks for BRCA1 and BRCA2 carriers vary with respect to observable and unobservable characteristics.
Design, setting, and participants: Probands were identified from a population-based, case-control study (Women's Environmental Cancer and Radiation Epidemiology [WECARE]) of asynchronous contralateral breast cancer conducted during the period of January 2000 to July 2004. Participants previously diagnosed with contralateral breast cancer or unilateral breast cancer were genotyped for mutations in BRCA1 and BRCA2. All participants had their initial breast cancer diagnosed during the period of January 1985 to December 2000, before the age of 55 years.
Main outcome measure: Incidence of breast cancer in first-degree female relatives of the probands was examined and compared on the basis of proband characteristics and on the basis of variation between families.
Results: Among the 1394 participants with unilateral breast cancer, 73 (5.2%) were identified as carriers of deleterious mutations (42 with BRCA1 and 31 with BRCA2). Among the 704 participants with contralateral breast cancer, 108 (15.3%) were identified as carriers of deleterious mutations (67 with BRCA1 and 41 with BRCA2). Among relatives of carriers, risk was significantly associated with younger age at diagnosis in the proband (P = .04), and there was a trend toward higher risk for relatives of contralateral breast cancer vs unilateral breast cancer participants (odds ratio, 1.4 [95% confidence interval, 0.8-2.4]; P = .28). In addition, there were significant differences in risk between carrier families after adjusting for these observed characteristics.
Conclusion: There exists broad variation in breast cancer risk among carriers of BRCA1 and BRCA2 mutations.
Figures
Similar articles
-
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112. JAMA. 2017. PMID: 28632866
-
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.Int J Cancer. 2005 Dec 20;117(6):988-91. doi: 10.1002/ijc.21273. Int J Cancer. 2005. PMID: 15986445
-
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.Breast Cancer Res Treat. 2010 Jan;119(1):221-32. doi: 10.1007/s10549-009-0394-1. Epub 2009 Apr 16. Breast Cancer Res Treat. 2010. PMID: 19370414
-
Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis.Breast. 2014 Dec;23(6):721-42. doi: 10.1016/j.breast.2014.10.005. Epub 2014 Nov 7. Breast. 2014. PMID: 25467311 Review.
-
BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review.Clin Oncol (R Coll Radiol). 2015 Sep;27(9):527-35. doi: 10.1016/j.clon.2015.06.001. Epub 2015 Jun 22. Clin Oncol (R Coll Radiol). 2015. PMID: 26113392 Review.
Cited by
-
The Association Between Breast Cancer Predisposing Genetic Variants and Multifocal, Multicentric Breast Cancer.Ann Surg Oncol. 2024 Dec;31(13):8891-8899. doi: 10.1245/s10434-024-16243-3. Epub 2024 Sep 27. Ann Surg Oncol. 2024. PMID: 39331289
-
Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.NPJ Breast Cancer. 2024 Jul 26;10(1):63. doi: 10.1038/s41523-024-00674-y. NPJ Breast Cancer. 2024. PMID: 39060255 Free PMC article.
-
RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid.Cancer Cell Int. 2024 Mar 29;24(1):118. doi: 10.1186/s12935-024-03299-0. Cancer Cell Int. 2024. PMID: 38553715 Free PMC article.
-
Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection.JAMA Surg. 2023 Dec 1;158(12):1275-1284. doi: 10.1001/jamasurg.2023.4770. JAMA Surg. 2023. PMID: 37792368 Free PMC article.
-
BRCA1-specific machine learning model predicts variant pathogenicity with high accuracy.Physiol Genomics. 2023 Aug 1;55(8):315-323. doi: 10.1152/physiolgenomics.00033.2023. Epub 2023 Jun 19. Physiol Genomics. 2023. PMID: 37335020 Free PMC article.
References
-
- Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401–8. - PubMed
-
- Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18:173–90. - PubMed
-
- Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Cancer Epidemiol Biomarkers Prev. 1999;8:741–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
